Glaxosmithkline Plc (GSK) 42.56 $GSK
GlaxoSmithKline Set to Possibly Rebound After Yesterday's Selloff of 3.50%
Comtex SmarTrend(R) - Fri Jun 24, 3:43PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $40.48 to a high of $41.77. Yesterday, the shares fell 3.5%, which took the trading range below the 3-day low of $41.54 on volume of 6.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 42.56 (+0.80)
After Yesterday's Decline of 3.50%, GlaxoSmithKline Offers Investors Better Value
Comtex SmarTrend(R) - Fri Jun 24, 3:42PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $40.48 to a high of $41.77. Yesterday, the shares fell 3.5%, which took the trading range below the 3-day low of $41.54 on volume of 6.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 42.56 (+0.80)
Mylan Launches Generic Avodart® Capsules
PR Newswire - Fri Jun 24, 10:44AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Dutasteride Capsules, 0.5 mg, the generic version of GlaxoSmithKline's Avodart® Capsules. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery. It may also be used with tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate.
MYL: 46.16 (+1.16), GSK: 42.56 (+0.80)
AstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
Arpita Dutt - Zacks Investment Research - Thu Jun 23, 8:15AM CDT
With the ACIP voting that AstraZeneca's (AZN) FluMist Quadrivalent should not be used in the 2016-2017 flu season, demand will be limited.
JNJ: 117.38 (+0.92), PFE: 34.59 (+0.12), AZN: 29.29 (+0.59), GSK: 42.56 (+0.80)
New Stock Research Reports for June 21, 2016
Sheraz Mian - Zacks Investment Research - Tue Jun 21, 1:44PM CDT
New Stock Research Reports for June 21, 2016
FB: 115.08 (+1.17), DD: 69.21 (+1.14), CAT: 78.22 (+1.79), GSK: 42.56 (+0.80), INTC: 32.99 (+0.70), PEP: 104.44 (+0.70)
Glaxo/Innoviva's Closed Triple Combination Tops Phase III
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:30AM CDT
Glaxo (GSK) and Innoviva (INVA) announced positive top-line data from the phase III FULFIL study on the closed triple combination therapy for the treatment of COPD.
INVA: 11.22 (+0.20), TBPH: 23.06 (+0.17), GSK: 42.56 (+0.80), BMY: 72.64 (+0.33)
Look for Shares of GlaxoSmithKline to Potentially Pullback after Yesterday's 3.24% Rise
Comtex SmarTrend(R) - Mon Jun 20, 2:15PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.62 to a high of $42.28. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $40.67 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 42.56 (+0.80)
SmarTrend Watching for Potential Pullback in Shares of GlaxoSmithKline After 3.24% Gain
Comtex SmarTrend(R) - Mon Jun 20, 2:13PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.62 to a high of $42.28. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $40.67 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 42.56 (+0.80)
February 2017 Options Now Available For GlaxoSmithKline (GSK)
DividendChannel.com - Mon Jun 20, 10:01AM CDT
Investors in GlaxoSmithKline plc saw new options begin trading today, for the February 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the...
GSK: 42.56 (+0.80)
Watch for GlaxoSmithKline to Potentially Rebound After Falling 2.13% Yesterday
Comtex SmarTrend(R) - Tue Jun 14, 1:10PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $39.76 to a high of $40.40. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $40.77 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 42.56 (+0.80)
Milner Therapeutics Institute Announces New Partnership With Japanese Pharmaceutical Company Shionogi
PR Newswire Europe - Mon Jun 13, 4:51AM CDT
CAMBRIDGE, England, June 13, 2016 /PRNewswire/ --
GSK: 42.56 (+0.80)
ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV
PR Newswire Europe - Fri Jun 10, 8:18AM CDT
LONDON, June 10, 2016 /PRNewswire/ --
PFE: 34.59 (+0.12), GSK: 42.56 (+0.80)
GlaxoSmithKline Falls 1.25% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 09, 1:54PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.84 to a high of $42.23. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $42.37 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 42.56 (+0.80)
Watch for GlaxoSmithKline to Potentially Rebound After Falling 1.25% Yesterday
Comtex SmarTrend(R) - Thu Jun 09, 1:52PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.84 to a high of $42.23. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $42.37 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 42.56 (+0.80)
Glaxo/J&J Sirukumab Positive in Rheumatoid Arthritis Study
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:01AM CDT
GlaxoSmithKline (GSK) and Johnson & Johnson's Janssen Biologics announced encouraging new phase III study data on rheumatoid arthritis candidate, sirukumab.
JNJ: 117.38 (+0.92), RTRX: 18.49 (+0.01), GSK: 42.56 (+0.80), BMY: 72.64 (+0.33)
NYSE Governance Services Announces 2016 Leadership Award Winners
BusinessWire - Thu Jun 09, 7:30AM CDT
NYSE Governance Services, a subsidiary of New York Stock Exchange (NYSE: ICE), today announced the winners and finalists of its 3rd annual Governance, Risk, and Compliance Leadership Awards. The awards program recognizes exemplary leaders in governance, risk and compliance.
SPLS: 8.95 (+0.26), LMT: 240.00 (+1.83), GE: 31.19 (+0.41), F: 13.40 (+0.22), RF: 9.45 (+0.33), NKE: 54.12 (-0.45), WMT: 72.10 (+0.35), SRE: 111.08 (+1.55), PEP: 104.44 (+0.70), JLL: 117.49 (+4.75), AAWW: 43.09 (+1.03), AGR: 43.81 (+0.50), ANF: 19.33 (+0.33), BANC: 19.60 (+0.35), AJG: 47.56 (+0.76), MA: 95.71 (+1.65), CMS: 43.59 (-0.06), FEYE: 16.88 (+0.59), INGR: 125.97 (+1.42), ETH: 33.00 (+0.10), ICE: 256.05 (+4.05), AHS: 40.31 (+0.83), EGBN: 50.45 (+2.77), INOV: 17.74 (+0.09), WFC: 47.91 (+0.94), GSK: 42.56 (+0.80), HPQ: 12.95 (+0.34), ORCL: 40.83 (+0.82), DRI: 67.98 (+0.80), MSEX: 39.50 (+0.13), GILD: 83.37 (+0.92), CVS: 94.02 (+0.29), TAHO: 13.27 (+0.13), OSK: 48.64 (+0.91)
GlaxoSmithKline (Zofran) Ondansetron Patent Report 2016 - Extension and Data Exclusivity Expiry Snapshot - Research and Markets
BusinessWire - Fri Jun 03, 9:35AM CDT
Research and Markets has announced the addition of the "Ondansetron - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)" report to their offering.
GSK: 42.56 (+0.80)
Glaxo/Innoviva Expedite Closed Triple Combination NDA Filing
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 8:40AM CDT
Glaxo (GSK) and Innoviva (INVA) will file an NDA in the U.S. for the closed triple combination therapy (FF/UMEC/VI) for the treatment of COPD by the end of 2016.
INVA: 11.22 (+0.20), TBPH: 23.06 (+0.17), GSK: 42.56 (+0.80), BMY: 72.64 (+0.33)
GlaxoSmithKline Set to Possibly Rebound After Yesterday's Selloff of 3.50%
Comtex SmarTrend(R) - Fri Jun 24, 3:43PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $40.48 to a high of $41.77. Yesterday, the shares fell 3.5%, which took the trading range below the 3-day low of $41.54 on volume of 6.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 42.56 (+0.80)
After Yesterday's Decline of 3.50%, GlaxoSmithKline Offers Investors Better Value
Comtex SmarTrend(R) - Fri Jun 24, 3:42PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $40.48 to a high of $41.77. Yesterday, the shares fell 3.5%, which took the trading range below the 3-day low of $41.54 on volume of 6.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 42.56 (+0.80)
Mylan Launches Generic Avodart® Capsules
PR Newswire - Fri Jun 24, 10:44AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Dutasteride Capsules, 0.5 mg, the generic version of GlaxoSmithKline's Avodart® Capsules. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery. It may also be used with tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate.
MYL: 46.16 (+1.16), GSK: 42.56 (+0.80)
AstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
Arpita Dutt - Zacks Investment Research - Thu Jun 23, 8:15AM CDT
With the ACIP voting that AstraZeneca's (AZN) FluMist Quadrivalent should not be used in the 2016-2017 flu season, demand will be limited.
JNJ: 117.38 (+0.92), PFE: 34.59 (+0.12), AZN: 29.29 (+0.59), GSK: 42.56 (+0.80)
New Stock Research Reports for June 21, 2016
Sheraz Mian - Zacks Investment Research - Tue Jun 21, 1:44PM CDT
New Stock Research Reports for June 21, 2016
FB: 115.08 (+1.17), DD: 69.21 (+1.14), CAT: 78.22 (+1.79), GSK: 42.56 (+0.80), INTC: 32.99 (+0.70), PEP: 104.44 (+0.70)
Glaxo/Innoviva's Closed Triple Combination Tops Phase III
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:30AM CDT
Glaxo (GSK) and Innoviva (INVA) announced positive top-line data from the phase III FULFIL study on the closed triple combination therapy for the treatment of COPD.
INVA: 11.22 (+0.20), TBPH: 23.06 (+0.17), GSK: 42.56 (+0.80), BMY: 72.64 (+0.33)
Look for Shares of GlaxoSmithKline to Potentially Pullback after Yesterday's 3.24% Rise
Comtex SmarTrend(R) - Mon Jun 20, 2:15PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.62 to a high of $42.28. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $40.67 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 42.56 (+0.80)
SmarTrend Watching for Potential Pullback in Shares of GlaxoSmithKline After 3.24% Gain
Comtex SmarTrend(R) - Mon Jun 20, 2:13PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.62 to a high of $42.28. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $40.67 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 42.56 (+0.80)
February 2017 Options Now Available For GlaxoSmithKline (GSK)
DividendChannel.com - Mon Jun 20, 10:01AM CDT
Investors in GlaxoSmithKline plc saw new options begin trading today, for the February 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the...
GSK: 42.56 (+0.80)
Watch for GlaxoSmithKline to Potentially Rebound After Falling 2.13% Yesterday
Comtex SmarTrend(R) - Tue Jun 14, 1:10PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $39.76 to a high of $40.40. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $40.77 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 42.56 (+0.80)
Milner Therapeutics Institute Announces New Partnership With Japanese Pharmaceutical Company Shionogi
PR Newswire Europe - Mon Jun 13, 4:51AM CDT
CAMBRIDGE, England, June 13, 2016 /PRNewswire/ --
GSK: 42.56 (+0.80)
ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV
PR Newswire Europe - Fri Jun 10, 8:18AM CDT
LONDON, June 10, 2016 /PRNewswire/ --
PFE: 34.59 (+0.12), GSK: 42.56 (+0.80)
GlaxoSmithKline Falls 1.25% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 09, 1:54PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.84 to a high of $42.23. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $42.37 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 42.56 (+0.80)
Watch for GlaxoSmithKline to Potentially Rebound After Falling 1.25% Yesterday
Comtex SmarTrend(R) - Thu Jun 09, 1:52PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.84 to a high of $42.23. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $42.37 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 42.56 (+0.80)
Glaxo/J&J Sirukumab Positive in Rheumatoid Arthritis Study
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:01AM CDT
GlaxoSmithKline (GSK) and Johnson & Johnson's Janssen Biologics announced encouraging new phase III study data on rheumatoid arthritis candidate, sirukumab.
JNJ: 117.38 (+0.92), RTRX: 18.49 (+0.01), GSK: 42.56 (+0.80), BMY: 72.64 (+0.33)
NYSE Governance Services Announces 2016 Leadership Award Winners
BusinessWire - Thu Jun 09, 7:30AM CDT
NYSE Governance Services, a subsidiary of New York Stock Exchange (NYSE: ICE), today announced the winners and finalists of its 3rd annual Governance, Risk, and Compliance Leadership Awards. The awards program recognizes exemplary leaders in governance, risk and compliance.
SPLS: 8.95 (+0.26), LMT: 240.00 (+1.83), GE: 31.19 (+0.41), F: 13.40 (+0.22), RF: 9.45 (+0.33), NKE: 54.12 (-0.45), WMT: 72.10 (+0.35), SRE: 111.08 (+1.55), PEP: 104.44 (+0.70), JLL: 117.49 (+4.75), AAWW: 43.09 (+1.03), AGR: 43.81 (+0.50), ANF: 19.33 (+0.33), BANC: 19.60 (+0.35), AJG: 47.56 (+0.76), MA: 95.71 (+1.65), CMS: 43.59 (-0.06), FEYE: 16.88 (+0.59), INGR: 125.97 (+1.42), ETH: 33.00 (+0.10), ICE: 256.05 (+4.05), AHS: 40.31 (+0.83), EGBN: 50.45 (+2.77), INOV: 17.74 (+0.09), WFC: 47.91 (+0.94), GSK: 42.56 (+0.80), HPQ: 12.95 (+0.34), ORCL: 40.83 (+0.82), DRI: 67.98 (+0.80), MSEX: 39.50 (+0.13), GILD: 83.37 (+0.92), CVS: 94.02 (+0.29), TAHO: 13.27 (+0.13), OSK: 48.64 (+0.91)
GlaxoSmithKline (Zofran) Ondansetron Patent Report 2016 - Extension and Data Exclusivity Expiry Snapshot - Research and Markets
BusinessWire - Fri Jun 03, 9:35AM CDT
Research and Markets has announced the addition of the "Ondansetron - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)" report to their offering.
GSK: 42.56 (+0.80)
Glaxo/Innoviva Expedite Closed Triple Combination NDA Filing
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 8:40AM CDT
Glaxo (GSK) and Innoviva (INVA) will file an NDA in the U.S. for the closed triple combination therapy (FF/UMEC/VI) for the treatment of COPD by the end of 2016.
INVA: 11.22 (+0.20), TBPH: 23.06 (+0.17), GSK: 42.56 (+0.80), BMY: 72.64 (+0.33)
